Replimune spent the spring as a near-failure story and the summer as a newly commercial oncolytic company. Two complete-response letters had left the lead virus looking unapprovable, the commercial bench largely gone, and the annual report carrying substantial-doubt language. The Food and Drug Administration then granted accelerated approval of TUDRIQEV with nivolumab for adults with unresectable advanced cutaneous melanoma after programmed-death blockade had already failed. The equity is no longer a binary filing option. It is a launch equity whose franchise still sits on a single-arm dataset and a survival trial that does not read out until the next decade.
The April cuts removed more than two hundred Massachusetts roles and left a much thinner operating company. That is why selling and administrative spend fell so hard in the fiscal first quarter. The August follow-on then put about $141 million of net cash back on the balance sheet and lifted the going-concern cloud the annual report had flagged. The label the agency published is thinner than the conference-circuit read: the efficacy-evaluable group is the subset with a non-injected lesion, and the agency's response rate sits well below the full-cohort figure management has been citing. Shareholders are buying a launch that has to be rebuilt from a hollowed-out commercial organization, against a label that already haircuts the trial narrative.
Cash at the June quarter-end plus the raise covers more than a year of the current plan, including launch scale-up. That is a solvency statement, not a commercial one. The next several quarters resolve whether TUDRIQEV finds a durable slot beside tumor-infiltrating lymphocyte therapy in the post-checkpoint setting, or whether a thin label, a rebuilt sales force, and a far-dated confirmatory survival study leave the present capitalization paying for a launch that has not yet printed product revenue.